JP2022511786A5 - - Google Patents

Info

Publication number
JP2022511786A5
JP2022511786A5 JP2021530785A JP2021530785A JP2022511786A5 JP 2022511786 A5 JP2022511786 A5 JP 2022511786A5 JP 2021530785 A JP2021530785 A JP 2021530785A JP 2021530785 A JP2021530785 A JP 2021530785A JP 2022511786 A5 JP2022511786 A5 JP 2022511786A5
Authority
JP
Japan
Prior art keywords
alkyl
group
substituted
unsubstituted
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021530785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511786A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/063876 external-priority patent/WO2020113182A1/en
Publication of JP2022511786A publication Critical patent/JP2022511786A/ja
Publication of JP2022511786A5 publication Critical patent/JP2022511786A5/ja
Pending legal-status Critical Current

Links

JP2021530785A 2018-11-30 2019-11-29 新規芳香族化合物によるナチュラルキラー細胞およびｉｌｃ３細胞の増殖 Pending JP2022511786A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862774114P 2018-11-30 2018-11-30
US62/774,114 2018-11-30
PCT/US2019/063876 WO2020113182A1 (en) 2018-11-30 2019-11-29 Expansion of natural killer cells and ilc3 cells with novel aromatic compounds

Publications (2)

Publication Number Publication Date
JP2022511786A JP2022511786A (ja) 2022-02-01
JP2022511786A5 true JP2022511786A5 (https=) 2023-08-03

Family

ID=69005918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021530785A Pending JP2022511786A (ja) 2018-11-30 2019-11-29 新規芳香族化合物によるナチュラルキラー細胞およびｉｌｃ３細胞の増殖

Country Status (13)

Country Link
US (1) US20230028680A1 (https=)
EP (1) EP3887508A1 (https=)
JP (1) JP2022511786A (https=)
KR (1) KR20210111762A (https=)
CN (1) CN113454207A (https=)
AU (1) AU2019387491A1 (https=)
BR (1) BR112021010245A2 (https=)
CA (1) CA3119427A1 (https=)
EA (1) EA202191508A1 (https=)
MX (1) MX2021006398A (https=)
PH (1) PH12021551241A1 (https=)
SG (1) SG11202105213XA (https=)
WO (1) WO2020113182A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220265712A1 (en) * 2019-06-14 2022-08-25 Celularity Inc. Populations of natural killer cells for treating cancers
US20220273716A1 (en) * 2019-07-25 2022-09-01 Celularity Inc. Populations of natural killer cells comprising a cd38 chimeric antigen receptor
US20220000919A1 (en) * 2020-01-29 2022-01-06 Celularity Inc. Placental derived natural killer cells for treatment of coronavirus infections
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
WO2022155585A2 (en) * 2021-01-15 2022-07-21 City Of Hope Methods of preparing and expanding type i innate lymphoid cells and therapeutic uses thereof
WO2023278628A1 (en) * 2021-06-29 2023-01-05 Celularity Inc. Human placental hematopoietic stem cell derived natural killer cells in acute myeloid leukemia (aml) remission with minimal residual disease (mrd) or relapsed/refractory aml
JPWO2023038037A1 (https=) * 2021-09-08 2023-03-16
IL315733A (en) 2022-04-08 2024-11-01 SHY Therapeutics LLC Compounds that Interact with RAS Superfamily Proteins for the Treatment of Cancer, Inflammatory, Basoplastic, and Fibrotic Diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5552267A (en) 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
DK1349918T3 (da) 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
EP2316919B1 (en) 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US20030187515A1 (en) 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
JP2005089352A (ja) * 2003-09-16 2005-04-07 Kissei Pharmaceut Co Ltd 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
PT2471904T (pt) 2005-12-29 2019-02-25 Celularity Inc População de células estaminais placentárias
CA2633980A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
JP5474533B2 (ja) * 2006-05-03 2014-04-16 シムライズ アーゲー Ａｈ受容体アンタゴニスト
CA2700613C (en) 2007-09-26 2022-09-20 Celgene Cellular Therapeutics Angiogenic cells from human placental perfusate
AU2013203936A1 (en) * 2008-10-30 2013-05-02 Novartis Ag Compounds that expand hematopoietic stem cells
RU2013120966A (ru) * 2010-10-08 2014-11-20 Эббви Инк. ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
BR112017014269A2 (pt) * 2014-12-31 2018-03-27 Anthrogenesis Corp células exterminadoras naturais e usos das mesmas
EA201890960A1 (ru) * 2015-10-15 2018-10-31 Селулэрити, Инк. Натуральные киллеры и клетки ilc3 и их применение
TWI752155B (zh) * 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
MX2019012431A (es) * 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.

Similar Documents

Publication Publication Date Title
JP2022511786A5 (https=)
Yan et al. Interleukin (IL)-12 and IL-23 and their conflicting roles in cancer
Candido et al. Cancer-related inflammation
JP2023171766A5 (https=)
Riether et al. Regulation of hematopoietic and leukemic stem cells by the immune system
Tymoszuk et al. In situ proliferation contributes to accumulation of tumor‐associated macrophages in spontaneous mammary tumors
JP6416131B2 (ja) 濃縮された腫瘍反応性ｔ細胞集団を腫瘍から作製する方法
US9925220B2 (en) Method of expanding double negative T cells
JP2022512766A (ja) 組み合わせがん免疫療法
He et al. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model
JP2008517948A5 (https=)
JP2016522232A5 (https=)
Gao et al. CXCL11 signaling in the tumor microenvironment
Yehudai‐Resheff et al. Abnormal morphological and functional nature of bone marrow stromal cells provides preferential support for survival of acute myeloid leukemia cells
JP7499698B2 (ja) 化合物及び幹細胞及び／又は前駆細胞の増殖におけるその使用
JP2020520367A5 (https=)
CN113454207A (zh) 用新型芳香族化合物扩增自然杀伤细胞和ilc3细胞
JP2024501127A (ja) 腫瘍浸潤リンパ球培地及びその使用
JP2021511359A (ja) キナーゼ依存的障害を処置するための化合物
Isvoranu et al. Therapeutic potential of interleukin-21 in cancer
Du et al. The different effects of IFN‐β and IFN‐γ on the tumor‐suppressive activity of human amniotic fluid‐derived mesenchymal stem cells
Ou et al. Heterocyclic-modified imidazoquinoline derivatives: Selective TLR7 agonist regulates tumor microenvironment against melanoma
JP2026510622A (ja) 幹細胞様メモリーｔ細胞をインビトロで誘導・増幅する方法
Guo et al. Manufacturing CAR-NK against tumors: Who is the ideal supplier?
BR112019026172A2 (pt) uso de uma célula-tronco mesenquimal